Company Moderna, Inc. Buenos Aires S.E.

Equities

MRNA

AR0666228538

Biotechnology & Medical Research

End-of-day quote Buenos Aires S.E. 03:30:00 31/05/2024 am IST 5-day change 1st Jan Change
9,670 ARS +1.68% Intraday chart for Moderna, Inc. -12.09% -.--%

Business Summary

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:

- revenue from product sales (95.7%) ;

- revenues from grants (4%);

- revenues from collaboration agreements (0.3%).

At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.

Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Number of employees: 5,600

Sales per Business

USD in Million2022Weight2023Weight Delta
Messenger RNA (mRNA) Medicines
100.0 %
19,263 100.0 % 6,848 100.0 % -64.45%

Sales per region

USD in Million2022Weight2023Weight Delta
Rest of World
52.5 %
7,298 37.9 % 3,598 52.5 % -50.70%
United States
27.7 %
5,150 26.7 % 1,895 27.7 % -63.20%
Europe
19.8 %
6,815 35.4 % 1,355 19.8 % -80.12%

Managers

Managers TitleAgeSince
Chief Executive Officer 51 01/11/01
Director of Finance/CFO 47 06/22/06
President 48 01/13/01
Chief Tech/Sci/R&D Officer - 03/23/03
Chief Tech/Sci/R&D Officer - 01/23/01
Investor Relations Contact - 01/19/01
Corporate Officer/Principal - -
Corporate Officer/Principal - 11/21/11
Corporate Officer/Principal - 11/20/11
General Counsel - 21/20/21

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 01/18/01
Director/Board Member 74 01/20/01
Director/Board Member 67 11/19/11
Founder 60 01/10/01
Founder 74 01/10/01
Chief Executive Officer 51 01/11/01
Director/Board Member 75 01/20/01
Director/Board Member 72 01/15/01
Director/Board Member 63 01/17/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 383,239,726 346,515,528 ( 90.42 %) 0 90.42 %

Shareholders

NameEquities%Valuation
Baillie Gifford & Co.
11.66 %
44,655,817 11.66 % 4 742 M $
Vanguard Fiduciary Trust Co.
10.20 %
39,036,872 10.20 % 4 145 M $
21,075,476 5.504 % 2 238 M $
BlackRock Advisors LLC
5.199 %
19,906,615 5.199 % 2 114 M $
14,452,035 3.775 % 1 535 M $
Fidelity Management & Research Co. LLC
3.550 %
13,591,755 3.550 % 1 443 M $
11,509,357 3.006 % 1 222 M $
Flagship Pioneering
2.525 %
9,666,038 2.525 % 1 026 M $
Thélème Partners LLP
1.912 %
7,321,797 1.912 % 777 M $
Geode Capital Management LLC
1.763 %
6,750,479 1.763 % 717 M $

Holdings

NameEquities%Valuation
5,859,375 8.81% 17,636,719 $
1,707,473 4.56% 11,508,368 $
5,059,338 12.18% 8,297,314 $

Company contact information

Moderna, Inc.

325 Binney Street

02142, Cambridge

+617 714 6500

http://www.modernatx.com
address Moderna, Inc.(MRNA)